|
|
|
|
|
|
Sponsored by: |
Genzyme |
Information provided by: | Genzyme |
ClinicalTrials.gov Identifier: | NCT00074971 |
People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the a-galactosidase A enzyme. Fabrazyme is a drug that helps to breakdown and remove certain types of fatty substances called "glycolipids." These glycolipids are normally present within the body in most cells. In Fabry disease, glycolipids build up in various tissues such as the liver, kidney, skin, and blood vessels because a-galactosidase A is not present, or is present in small quantities. The build up of glycolipid ("globatriaosylceramide" or "GL-3") levels in these tissues in particular is thought to cause the clinical symptoms that are common to Fabry disease. This study will test the safety and efficacy of Fabrazyme in the treatment of patients with Fabry disease.
Condition | Intervention | Phase |
Fabry Disease |
Drug: Fabrazyme (agalsidase beta) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Multi-Center, Open-Label Extension Study of the Safety and Efficacy of Recombinant Human a-Galactosidase A (r-haGAL) Replacement in Patients With Fabry Disease |
Estimated Enrollment: | 58 |
Study Start Date: | October 1999 |
Estimated Study Completion Date: | December 2004 |
Ages Eligible for Study: | 16 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion criteria:
Show 20 Study Locations |
Genzyme |
US FDA Approved Full Prescribing Information for Fabrazyme® 
  |
Study ID Numbers: | AGAL-005-99 |
First Received: | December 24, 2003 |
Last Updated: | July 16, 2007 |
ClinicalTrials.gov Identifier: | NCT00074971 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|